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a b s t  r  a c  t
The aim  of  the present  work  was  to develop  and  validate  a multi-residue  method  for  the  analysis  of
33  human  and  veterinary  pharmaceuticals  (non-steroidal  anti-inﬂammatory  drugs  (NSAIDs)/analgesics,
antibiotics  and psychiatric  drugs),  including  some  of  their  metabolites,  in  several  aqueous  environ-
mental  matrices:  drinking  water,  surface  water  and  wastewaters.  The  method  is based  on solid  phase
extraction  (SPE)  followed  by  ultra-high  performance  liquid  chromatography-tandem  mass  spectrometry
(UHPLC–MS/MS)  and  it  was  validated  for different  aqueous  matrices,  namely  bottled  water,  tap water,
seawater,  river  water  and  wastewaters,  showing  recoveries  between  50%  and  112%  for  the  majority  of
the  target  analytes.
The developed  analytical  methodology  allowed  method  detection  limits  in the  low  nanograms  per  liter
level.  Method  intra-  and inter-day  precision  was under  8% and  11%,  respectively,  expressed  as  relative
standard  deviation.  The  developed  method  was applied  to  the  analysis  of  drinking  water  (bottled  and  tap
water),  surface  waters (seawater  and river  water)  and  wastewaters  (wastewater  treatment  plant  (WWTP)
inﬂuent  and  efﬂuent).  Due  to  the  selectivity  and  sensitivity  of  the optimized  method,  it was  possible
to  detect  pharmaceuticals  in all  the  aqueous  environmental  matrices  considered,  including  in  bottled
water  at concentrations  up to  31  ng  L−1 (salicylic acid).  In general,  non-steroidal  anti-inﬂammatory
drugs/analgesics  was  the  therapeutic  group  most  frequently  detected,  with  the highest  concentrations
found  in  wastewaters  (acetaminophen  and  the metabolite  carboxyibuprofen  at levels  up  to 615  and
120  g  L−1,  respectively).. Introduction
The consumption of pharmaceuticals may  vary considerably
rom country to country [1], and no information for the total use
f pharmaceuticals is available. They can be sold as prescription
r over-the-counter medicines [2] and pharmaceuticals have an
mportant role in the treatment and prevention of diseases in both
uman and veterinary medicine [3]. Additionally, they can be also
sed as growth promoters in animals [4].
Pharmaceuticals are continually released into the environment
ainly as a result of their excretion in urine and/or feces, manufac-
uring processes, and disposal of unused or expired products [5].
esides that, pharmaceuticals can also directly enter the terrestrial
∗ Corresponding author.
E-mail address: cmm@isep.ipp.pt (C. Delerue-Matos).environment via different types of manure, slurries or other types
of biosolids [4] and, after that, reach the aquatic environment due
to soils run-off.
The  pharmaceutical market has been growing over the last
decades as well as the knowledge on the environmental impact
of pharmaceuticals to ecosystems [6]. Once released into the envi-
ronment, pharmaceuticals and their bioactive metabolites can be
transported and distributed to water, soil or sediments, due to
different factors, such as the physicochemical properties of the
compounds and the characteristics of the receiving environment.
Pharmaceuticals can accumulate in biota and induce adverse effects
in aquatic or terrestrial organisms as well [5].
Wastewaters generated by hospital, industrial and domestic
sources are pointed out as one of the most important source of phar-
maceuticals to the aquatic environment [7]. Many pharmaceuticals,
their metabolites and transformation products are incompletely
removed in conventional wastewater treatment plants (WWTP)
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Cnd thus discharged into the environment [8]. Therefore, the
resence of pharmaceuticals at trace levels (nanograms to low
icrograms per liter) has been reported in wastewaters, surface
aters, groundwater’s and, to a lesser extent, drinking waters
9–13]. In this way, sensitive and reliable analytical methods must
e developed for the detection and quantiﬁcation of pharmaceuti-
als in the aquatic environment.
Sample  preparation is considered to be a fundamental step in
nvironmental analytical procedures [14] and has to be selective,
heap, quick, and environmentally friendly [15]. The use of solid
hase extraction (SPE) for the sample preparation has increased
ver the last years, because it is easy to operate, has increased
electivity with many new sorbents, and has the possibility to inter-
ace for automation and robotics [14]. Its versatility (puriﬁcation,
race enrichment, desalting, derivatization, and class fractionation)
llows SPE to be the ﬁrst choice to be used in sample preparation
f liquid samples.
Tandem mass spectrometry (MS) is considered to be a high
esolution and sensitive detection technique due to its speciﬁcity
nd low limits of detection [16]. Each year, LC–MS/MS become
ven more sensitive and is an important detection method in envi-
onmental analysis [9]. Numerous studies have demonstrated its
istinct advantages for trace analysis of pharmaceuticals in envi-
onmental samples [9,10,12].
The development of accurate multi-residue analytical method-
logies for the simultaneous analyses of trace levels of human and
eterinary pharmaceuticals in a wide range of aquatic environ-
ental matrices is useful and necessary, in order to be possible
o gather data on different ways of entrance of pharmaceuticals
nto the environment and, at the same time, evaluate the impact
nd distribution of either human and veterinary medicines in the
quatic environment. In the present study, an automated off-line
PE procedure followed by UHPLC coupled to triple quadrupole tan-
em MS  with electrospray ionization source (ESI) was  developed
or the determination of 33 human and veterinary pharmaceuti-
als and some of their main metabolites, including non-steroidal
nti-inﬂammatory drugs (NSAIDs)/analgesics, antibiotics, and psy-
hiatric drugs. Different chromatographic and mass spectrometry
arameters were optimized. A versatile SPE protocol was  also
eveloped in order to be applied to a great diversity of aquatic
nvironmental matrices (e.g. wastewater, surface water, drinking
ater). Finally, the optimized method was successfully applied to
ixteen samples embracing drinking water (bottled and tap water),
urface water (seawater and river water) and wastewater (WWTP
nﬂuent and efﬂuent), allowing the evaluation of the distribution
f the selected human and veterinary pharmaceuticals through the
quatic environment.
. Materials and methods
.1. Reagents, solvents and materials
All pharmaceuticals and isotopically labelled standards were of
igh purity grade (≥98%) and their physicochemical characteristics
nd suppliers are listed in Table SM1  of Supplementary Material.
Stock  standard solutions (at a concentration of 1000 mg L−1)
ere prepared on a weight basis in acetonitrile, with exception
f naproxen and diclofenac that were prepared in acetoni-
rile:methanol (50:50, v/v), since these substances are very slightly
oluble in pure acetonitrile and freely soluble in methanol [17];
nd psychiatric drugs that were prepared in methanol. The antibi-
tics oﬂoxacin, ciproﬂoxacin, and enroﬂoxacin as well as the
sotopically labelled standard ciproﬂoxacin-d8 were prepared in
ethanol adding NaOH 1 M as described by Ibán˜ez, M.  et al. [18].
arbamazepine-d10 (100 mg  L−1), venlafaxine-d6 (100 mg  L−1),diazepam-d5 (1000 mg  L−1), and norsertraline (100 mg L−1) were
purchased as free base in methanol.
All stock standard solutions were stored at −20 ◦C  and renewed
every 3 months, with the exception of antibiotics that were pre-
pared monthly because of their limited stability. Working standard
solutions containing all pharmaceuticals were prepared in acetoni-
trile:ultrapure water (30:70, v/v) by mixing appropriate amounts of
each stock standard solution. These solutions were prepared before
each analytical run.
A  mixture with all isotopically labelled standards was prepared
to be used for internal standard calibration.
Acetonitrile LC–MS grade was  supplied by Biosolve
(Valkenswaard, Netherland) and methanol LC–MS Ultra
CHROMASOLV
®
was purchased from Sigma-Aldrich. Hydrochloric
acid 37% was obtained from Carlo Erba (Rodano, Italy), and formic
acid 98% PA-ACS and ethylenediaminetetraacetic acid disodium
salt 2-hydrate (Na2EDTA) (assay 99.9–101.0%) were obtained
from Panreac (Barcelona, Spain). Ultrapure water (resistivity
of 18.2 M cm)  was produced using a Simplicity 185 system
(Millipore, Molsheim, France).
All chromatographic solvents were ﬁltered through a 0.22 m
nylon membrane ﬁlter (Fioroni Filters, Ingré, France) using a vac-
uum pump (Dinko D-95, Barcelona, Spain) and degassed for 15 min
in an ultrasonic bath (Sonorex Digital 10P, Bandelin DK 255P,
Germany). Before the UHPLC–MS/MS analysis, sample extracts
were ﬁltered through 0.22 m PTFE syringe ﬁlters (Specanalitica,
Carcavelos, Portugal). SPE cartridges Strata-X (200 mg,  3 mL)  from
Phenomenex (California, USA) and Oasis MCX  (150 mg,  6 mL)  from
Waters (Milford, Massachusets, USA) were used in the study of the
SPE sorbent.
2.2. Sampling sites and sample collection
Sixteen samples were analyzed using the optimized analytical
methodology. Two samples were collected for each type of water
with the exception of seawater for which six samples were col-
lected. Tap water samples were obtained from the tap of laboratory
and in a private house located in the Porto area, whilst bottled
waters were purchased in the local market. River samples were
taken from Lis river, which crosses the city of Leiria in the center
region of Portugal. Seawater samples from the Atlantic Ocean were
collected in Porto coastal area from beaches with different bathing
water quality (excellent, good and sufﬁcient) [19]. Two beaches
for each classiﬁcation were selected. Wastewater samples (inﬂuent
and efﬂuent) were collected in two WWTPs located in the center
region of Portugal (Leiria, Portugal). WWTP  inﬂuent and efﬂuent
were 24 h composite samples, whereas the other types of waters
were grab samples. Samples were collected in 2015.
Amber glass bottles pre-rinsed with ultrapure water were
used for sample collection. After reception in the laboratory,
wastewaters and river water were ﬁltered through 0.45 m
nylon membrane ﬁlters (Fioroni Filters, Ingré, France) followed
by 0.22 m nylon membrane ﬁlters (Fioroni Filters, Ingré, France),
while tap water and seawater were only ﬁltered through 0.22 m
nylon membrane ﬁlters (Fioroni Filters, Ingré, France).
2.3. Analytical method
SPE cartridges were conditioned with 5 mL  of methanol fol-
lowed by 5 mL  of ultrapure water and 5 mL  of ultrapure water
at pH 2 using a vacuum system manifold (Chromabond, Düren,
Germany). A suitable volume of a 0.1 M Na2EDTA solution was
added to the water samples to achieve a ﬁnal concentration of 0.1%
(g solute/g solution). 250 mL  of tap water, bottled water, seawater,
and river water, 100 mL  of WWTP  efﬂuent or 50 mL  of WWTP  inﬂu-
Fig. 1. MRM  chromatogram of a standard mixture at 100 g L−1 of  the selected pharmaceuticals analyzed in the negative (i) and positive (ii) ionization mode.
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ant with pH adjusted to 2 with concentrated HCl were percolated
hrough the cartridge. Then, the cartridges were rinsed with 5 mL
f ultrapure water and dried under vacuum for 60 min  to remove
he excess of water. Finally, the elution was performed with 10 mL
f methanol. Extracts were evaporated under a gentle stream of
itrogen and reconstituted with 500 L of acetonitrile:ultrapure
ater  (30:70, v/v). Lastly, 5 L of a mixture of isotopically labelled
tandards was added in order to obtain a ﬁnal concentration
f 7.5 g L−1 for salicylic acid-d4, 150 g L−1 for acetaminophen-
4,  75 g L−1 for  ibuprofen-d3, 10 g L−1 for  carbamazepine-d10
nd  for ﬂuoxetine-d5, 20 g L−1 for venlafaxine-d6, 40 g L−1 for
iazepam-d5, 100 g L−1 for  ciproﬂoxacin-d8 and azithromycin-
3, and 50 g L−1 for sulfamethoxazole-d4.
Quantiﬁcation of pharmaceuticals was performed in a Nexera
ltra-High Performance Liquid Chromatography system (Shi-
adzu Corporation, Kyoto, Japan) equipped with two  solvent
elivery modules, a degasser, an autosampler, a column oven,
nd coupled to a triple-quadupole mass spectrometer detec-
or LCMS-8030 with an electrospray ionization source (ESI).
SAIDs/analgesics were analysed in negative ionization mode,
hile antibiotics and psychiatric drugs were determined in the pos-
tive ionization mode. Different chromatographic conditions were
sed for each ionization mode. NSAIDs/analgesics were analysed
sing previously optimized conditions [20]. Brieﬂy, chromato-
raphic separation was achieved using a Kinetex C18 column
150 × 2.1 mm i.d., 1.7 m particle size) from Phenomenex (Cali-
ornia, USA), using ultrapure water as eluent A and acetonitrile as
luent B at a ﬂow rate of 0.22 mL/min. The gradient elution was:
–1.0 min, 30%–35.6% B; 1.0–2.0 min, 35.6%–100% B; 2.0–6.0 min,
00% B; 6.0–6.5 min, return to initial conditions; 6.5–10.5 min, re-
quilibration of the column.
For  positive ionization mode, the chromatographic conditions
ere optimized and chromatographic separation was  carried out
n a CortecsTM UPLC
®
C18+ column (100 × 2.1 mm i.d.; 1.6 m par-
icle size) from Waters (Milford, Massachusets, USA). Eluent A was
.1% formic acid in ultrapure water and eluent B was  acetonitrile
t a ﬂow rate of 0.3 mL  min−1. The gradient elution started with 5%
f eluent B, increasing to 100% B in 3 min, maintained 100% B dur-
ng 0.5 min  and then, returned to initial conditions within 0.5 min.
he column was re-equilibrated for 3 min  before the next injection.
n both modes, the autosampler was operated at 4 ◦C,  an injec-
ion volume of 5 L was used and column temperature was kept at
0 ◦C.  Lab Solutions LC–MS software (Shimadzu Corporation, Kyoto,
apan) was used for system control and data processing.
Source dependent parameters were optimized by the direct
njection of a standard mixture solution 10 mg  L−1 for positive ion-
zation mode, whereas for negative mode the MS/MS  conditions are
escribed in a previous work [20] and are the following: desolvation
ine temperature (DLT) was set at 250 ◦C  and heat block tempera-
ure (HBT) at 300 ◦C;  interface voltage (IV) at 5.0 kV; nebulizing gas
NGF) and drying gas (DGF) at a ﬂow rate of 2.6 and 12.5 L min−1,
espectively. For positive ionization mode, the optimized condi-
ions (see subsection 3.1.1) were as follows: DLT: 300 ◦C;  HBT:
25 ◦C; IV: 5.0 kV; NGF: 2.6 L min−1 and  DGF:15.0 L min−1. In both
onization modes, nitrogen was used as nebulizing and drying gas,
nd argon was used as collision induced dissociation gas at a pres-
ure of 230 kPa. A dwell time of 25 ms  and of 15 ms  was  used in
egative and positive ionization, respectively.
Multiple reaction monitoring (MRM)  is a method used in MS/MS
n which an ion of a particular mass is selected in the ﬁrst stage of
 tandem mass spectrometer and an ion product of a fragmenta-
ion reaction of the precursor ion is selected in the second mass
pectrometer stage, formed by collision-induced dissociation, for
etection. The signal represents the precursor-to-product ion tran-
ition for a speciﬁc ion pair. The most intense product was  set
s quantiﬁer ion whereas the second most intense was  used asqualiﬁer ion. Detailed data on the optimized mass spectrometry
parameters (precursor ions, quantiﬁer and qualiﬁer ions, and ion
ratio) as well as the corresponding internal standard used for quan-
tiﬁcation purposes is given in Table SM2  (Supplementary material).
2.4. Method validation
The performance of the method was evaluated through the
estimation of the linearity, extraction recoveries, method detec-
tion limits (MDLs), method quantiﬁcation limits (MQLs), precision
as repeatability expressed as relative standard deviation (%RSD),
reproducibility and matrix effects (ME) for each type of water sam-
ple.
Linearity was  established by setting calibration curves (solvent
and matrix matched) using linear regression analysis with concen-
trations in the range of 5–250 g L−1. Quantiﬁcation of the analytes
was performed by the internal standard approach. Recoveries were
determined by comparing concentrations obtained after the SPE
procedure, calculated by internal standard calibration, with the
initial fortiﬁcation levels. Since water samples can contain target
compounds, blanks (non-spiked samples) were also analyzed and
the levels found subtracted from those obtained for spiked samples.
MDLs and MQLs were determined as the minimum amount of ana-
lyte detectable with a signal-to-noise ratio of 3 and 10, respectively.
The limits were determined using real samples whenever possible,
otherwise spiked samples were used. Method precision was deter-
mined by intra- and inter-day analysis (%RSD). Three standards
mixtures containing all the analytes at a ﬁnal concentration of 25,
50, and 100 g L−1 were  used and six successive injections in one
day and six consecutive days (triplicate injections) was performed,
respectively. To assess the ME  in all types of waters, the slope of
the matrix matched calibration curve was compared with the slope
of the calibration curve prepared in solvent (acetonitrile:ultrapure
water  (30:70, v/v)). A blank (sample without addition of standards)
was simultaneously assayed in order to subtract the concentration
of the target analytes present in the sample. ME  was calculated
according to Eq. (1) [9,21], respectively. A value of zero indicates
that there is no ME,  while for a positive value there is an ion
enhancement signal and for a negative value an ion suppression
signal.
Signal supression(%)  =
(
slopematrix-matched
slopesolvent
− 1
)
× 100 (1)
3. Results and discussion
3.1. UHPLC–MS/MS
3.1.1. Ion source parameters
Source-dependent parameters such as DLT, HBT, IV, NGF, and
DGF are key parameters to enrich the instrumental sensitivity [22]
and, therefore they were studied. For NSAIDs/analgesics pharma-
ceuticals the source-dependent parameters were used as described
in Paíga, P. et al. [20], while for pharmaceuticals analyzed in pos-
itive ionization mode the parameters were optimized. In the case
of DLT, temperatures from 200 to 300 ◦C  were tested and it was
observed an increase of the signal from 220 to 225 ◦C,  being con-
stant therefore for psychiatric drugs. However, for antibiotics the
signal increased with the increment of the temperature. Thus, a
temperature of 300 ◦C  was  selected, since antibiotics showed lower
sensitivity when compared with psychiatric drugs. For HBT, tem-
peratures between 200 and 500 ◦C  were studied and, in general,
high sensitivity was observed for all the compounds using a tem-
perature of 425 ◦C.  The inﬂuence of IV in the analytical signal was
evaluated between 0 and 5 kV and it was noticed an increase in the
signal with an increment in IV. A maximum signal was  achieved
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dor 5 kV, which was selected. NGF was studied between 0.5 and
.0 L min−1 and  it was observed an increase of the analytical signal
rom 0.5 to 2.6 L min−1 and after that a decrease. The highest sig-
al intensity was obtained using 2.6 L min−1. Lastly, DGF was varied
etween 10 and 20 L min−1 and a maximum response was  obtained
or a ﬂow rate of 15 L min−1.
.1.2. Dwell time optimization
Using  MRM  for quantiﬁcation Q1 and Q3 are set to ﬁlter speciﬁc
ons as they pass through the ion optics. It is the dwell and the pause
imes together with the number of MRM  transitions monitored
hat determine the cycle time and thus the number of data points
btained across a given peak [23]. While very short dwell times
an be used for extended compound screening, higher dwell times
re desirable for better Signal-to-Noise ratio. Thus, setting proper
well time is necessary to achieve the best quality and quantity of
ata.
Different dwell times were studied in the interval of 1.0–100 ms.
or antibiotics and psychiatric drugs, it was observed a constant
nalytical signal and a good reproducibility (RSD <5%) in the range
f dwell time between 1.0 (RSD = 4.54%) and 15 ms  (RSD = 3.09%).
fter that, an increase of the dwell time led to a decrease of the
nalytical signal with RSD values reaching 28%. Therefore, the best
ompromise between the analytical signal and the reproducibility
as achieved using 15 ms  for antibiotics and psychiatric drugs.
.1.3. Chromatographic separation
Thirty-three human and veterinary pharmaceuticals
NSAIDs/analgesics, antibiotics, and psychiatric drugs) were
tudied in the present work. For NSAIDs/analgesics (negative
onization mode), chromatographic analysis was  performed as
escribed in Paíga, P. et al. [20]. For the remaining pharmaceuticals
positive ionization mode), the chromatographic conditions were
ptimized by evaluating different chromatographic columns,
obile phases, modes of elution, ﬂow rates and column temper-
tures. The complexity of some compounds may  cause problems
uring LC analysis, which often results in broad or tailing peaks,
oor resolution or some shape issues due to an increased retention
24]. It was observed that for psychiatric drugs, 25% of acetonitrile
as the initial maximum amount of organic solvent allowed for a
ood peak resolution, otherwise fronting and tailing peaks were
btained. In the other hand, for antibiotics at least 50% of organic
olvent (acetonitrile) in the initial conditions was needed. It should
e noted that even with that initial proportion of eluents, the
ailing and fronting is not observed but large peaks were achieved.
The performance of two chromatographic columns was  eval-
ated (Fig. SM1, Supplementary material). Using Kinetex C18
olumn, the best peak resolution was achieved with 10% of ACN
n the initial conditions of the gradient elution. Peaks well deﬁned
ere obtained for psychiatric drugs, however almost all antibi-
tics showed a bad peak resolution (Fig. SM1-A, Supplementary
aterial). Replacing the stationary phase by the column CortecsTM
PLC
®
C18+  (100 × 2.1 mm,  1.6 m)  and using the best chromato-
raphic conditions achieved for Kinetex C18 column, in general,
 much better peak resolution was observed for all pharmaceu-
icals. Therefore, the column CortecsTM UPLC
®
C18+ was  used for
he chromatographic analysis in the positive ionization mode. Dif-
erent mobile phases comprising several combinations of aqueous
nd organic eluents were tested in order to provide a better peak
esolution and a good sensitivity as well. Both elution modes (iso-
ratic and gradient) were tested. The best performance for all the
harmaceuticals was obtained using 0.1% formic acid in ultra-
ure water (A) and acetonitrile (B) in the mobile phase and a
radient elution as follows, initial conditions: 5% B; 0.0–3.0 min,
–100% B; 3.0–3.5 min, 100% B; 3.5–4.0 min, return to initial con-
itions; 4.0-7.0 min, re-equilibration of the column. The ﬂow ratewas optimized to 0.3 mL  min−1. A representative chromatogram of
a 100 g L−1 standard mixture of the selected pharmaceuticals is
present in Fig. 1.
3.2. Solid phase extraction optimization
3.2.1. Optimization of the SPE sorbent, sample pH adjustment
and  addition of Na2EDTA
The  performance of the polymeric sorbent Strata-X and of the
mixed mode polymeric and cation exchange sorbent Oasis MCX  on
the extraction of the selected human and veterinary pharmaceuti-
cals was evaluated. The effect of sample’s pH in the recoveries of
the selected pharmaceuticals was  assessed for pH 2, 9, and without
pH adjustment. Concentrated HCl or NaOH was used to adjust sam-
ple’s pH. Different sample volumes (25, 50, 100, 250, and 500 mL)
were also studied. Extraction efﬁciency of certain pharmaceuticals,
like antibiotics, can be improved by adding Na2EDTA to the sam-
ples, because soluble metals bound to the chelating agent, releasing
the analyte and increasing the extraction efﬁciency [25]. Thus, the
effect of adding Na2EDTA, prior to extraction, in the recovery of the
selected pharmaceuticals was  also evaluated. Reconstitution sol-
vent using different organic solvents (acetonitrile and methanol)
and mixtures of solvents (methanol:ultrapure water (1:1, v/v), ace-
tonitrile:ultrapure water (1:1, v/v), methanol:ultrapure water (3:7,
v/v), acetonitrile:ultrapure water (3:7, v/v), methanol:ultrapure
water with 0.1% formic acid (3:7, v/v), and acetonitrile:ultrapure
water  with 0.1% formic acid (3:7, v/v)) was  also studied. All the
optimizations were performed using 250 mL of ultrapure water
and the extracts were reconstituted with 1 mL  of acetonitrile. The
obtained recoveries for the different tested conditions are present
in the radar charts shown in Fig. 2.
Using Strata-X, recoveries increased for carboxyibuprofen,
ibuprofen,  salicylic acid, clarithromycin, azithromycin, norsertra-
line, and sertraline at sample pH 2, acetylsalicylic acid, salicylic
acid, trimethoprim, citalopram, and venlafaxine without sample
pH adjustment, and trimethoprim, sulfadimethoxine, norﬂuoxe-
tine and venlafaxine at sample pH 9. A decrease of recoveries
was obtained for sulfapyridine, norﬂuoxetine, and trazodone at
sample pH 2, hydroxyibuprofen, sulfadimethoxine, azithromycin,
and 10,11-epoxycarbamazepine without sample pH adjustment,
and diclofenac, ibuprofen, naproxen, clarithromycin, azithromycin,
norsertraline, sertraline, paroxetine, and trazodone at sample pH
9, when Na2EDTA was  added. Recoveries were constant for the
remaining pharmaceuticals.
On  the other hand, for Oasis MCX  it was observed that,
in all pH range, low recoveries were obtained for almost all
NSAIDs/analgesics and antibiotics when Na2EDTA was added to the
sample, with the exception of acetaminophen that had the highest
recovery (between 81.6 to 96.3%), whereas carboxyibuprofen was
not detected (Fig. 2). In the case of psychiatric drugs, the behaviour
observed was opposite and high recoveries were obtained with
the addition of Na2EDTA. Low recoveries were only obtained
for norﬂuoxetine at sample pH 2 and 10,11-epoxycarbamazepine
without  sample pH adjustment. For ciproﬂoxacin, enroﬂoxacin, and
oﬂoxacin, low recoveries (<10%) were achieved using both types of
sorbents in all tested conditions. For trimethoprim, a lower recov-
ery (in all pH range) was  achieved (<30%) using Oasis MCX  without
Na2EDTA addition than when the chelating agent was  added. Using
Strata-X, trimethoprim showed a good recovery in all experiments.
For all the studied pH’s the same behaviour was obtained for sul-
fonamide antibiotics and the high recoveries were achieved using
Strata-X. After the addition of Na2EDTA, sulfonamides’ recover-
ies remained constant using Strata-X, but decreased when Oasis
MCX was  used. Carbamazepine, citalopram, and venlafaxine had
constant recoveries in all studied conditions and no inﬂuence of
Fig. 2. Recoveries obtained in the study of solid phase extraction sorbent, sample pH adjustment (pH 2, without pH adjustment, and sample pH 9), and addition or not addition
of  Na2EDTA  (NSAIDs/analgesics: 1- Acetaminophen, 2- Acetylsalicylic acid, 3- Carboxyibuprofen, 4- Diclofenac, 5- Hydroxyibuprofen, 6- Ibuprofen, 7- Naproxen, 8- Nime-
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tulide,  9- Ketoprofen, 10- Salicylic acid; Antibiotics: 11- Ciproﬂoxacin, 12- Enroﬂoxa
7- Sulfadimethoxine, 18- Sulfadiazine, 19- Sulfamethoxazole, 20- Oﬂoxacin, 21- Cl
5- Carbamazepine, 26- Fluoxetine, 27- Sertraline, 28- Citalopram, 29- Venlafaxine
orbent, sample’s pH or addition of Na2EDTA was veriﬁed in the
ecovery results. In the case of paroxetine, for both types of SPE
orbents at pH 2, no difference was observed by the addition of
a2EDTA. For sertraline and trazodone recoveries were high using
asis MCX  with the addition of Na2EDTA.
A marked decrease in the recovery of NSAIDs/analgesics and
ntibiotics using Oasis MCX  was observed when Na2EDTA was
dded (Fig. 2). Although several studies mentioned the importance
f adding a cation complexing agent (Na2EDTA) to chelate metals
nd to minimize interferences for some pharmaceuticals [9,26], our
esults are in agreement with literature [27,28], where a decrease
f recoveries for some pharmaceuticals was also observed when
a2EDTA was added. A possible justiﬁcation for this is that when
he Na2EDTA is present in excess, it chelates not only metals but
lso organic compounds [27].
Comparing the performance of both sorbents could be con-
luded that Strata-X allowed higher recoveries for the majority of
he analysed pharmaceuticals. This could be due to a low reten-
ion of target compounds in Oasis MCX, since this mixed sorbent
as a lower amount of reversed-phase sorbent comparatively to
trata-X.
For almost all pharmaceuticals, the highest recoveries were
btained when sample pH was adjusted to 2. These results can
e explained by the presence of acidic functional groups in the
olecular structure of many pharmaceuticals, therefore lowering
H under their pKa values enhances the presence of neutral forms
nd their interaction with the reversed-phase sorbent.
Despite of the good recoveries found for some pharmaceuti-
als using Oasis MCX, for the majority of the selected compounds
he best recoveries were achieved using Strata-X cartridges, with3- Trimethoprim, 14- Sulfamethoxypiridine, 15- Sulfapyridine, 16- Sulfamethazine,
mycin, 22- Azithromycin; Psychiatric drugs: 23- Norsertraline, 24- Norﬂuoxetine,
aroxetine, 31- Trazodone, 32- Diazepam, 33- 10,11-Epoxycarbamazepine).
sample pH adjusted to 2 and adding Na2EDTA to the sam-
ple. The recoveries of NSAIDs/analgesics ranged from 72.5% for
acetylsalicylic acid to 111.5% for nimesulide with exception of
acetaminophen (recovery of 27.8%). For most of pharmaceuticals,
our recoveries were in accordance with results obtained by Gros,
M. et al. [9] and Weigel, S. et al. [29] using polymeric sorbents.
A similar recovery for acetaminophen was obtained by Weigel,
S. et al. [29] and the low recovery obtained might be justiﬁed by
its ready water solubility limiting the retention of acetaminophen.
For antibiotics, recoveries were between 67.2% for clarithromycin
and 97.8% for trimethoprim, with the exception of ciproﬂoxacin,
enroﬂoxacin, and oﬂoxacin, with recoveries lower than 11%. Low
recoveries (about 30%) for ciproﬂoxacin and oﬂoxacin were also
obtained by S. Castiglioni et al. [30], which pointed out the step of
evaporation to dryness as the reason for the low recoveries for these
antibiotics. For psychiatric drugs, recoveries ranged from 52.7% to
111.5% for trazodone and diazepam, respectively.
3.2.2. Reconstitution solvent after SPE extraction
None of the studied conditions previously described in
subsection 3.2.1., allowed obtaining good recoveries for the ﬂuo-
roquinolone antibiotics ciproﬂoxacin, enroﬂoxacin, and oﬂoxacin.
Fluoroquinolones have an amphoteric behaviour (pKa = 5 and
pKa = 8–9) and their solubility depend of the pH [31]. Thus, differ-
ent reconstitution solvents were tested, embracing 100% of organic
solvents or mixtures of solvents. The obtained results are present
in Fig. SM2  (Supplementary material). Using 100% of acetonitrile or
100% of methanol low recoveries were achieved, namely: 1.8, 17.1,
and 13.5% for 100% of acetonitrile and 11.9, 53.2, and 50.1% for 100%
methanol, for ciproﬂoxacin, enroﬂoxacin, and oﬂoxacin, respec-
Fig. 3. Sample volume breakthrough in (A) river water; (B) WWTP  efﬂuent, and (C) WWTP  inﬂuent (1- Acetaminophen, 2- Acetylsalicylic acid, 3- Carboxyibuprofen, 4-
Diclofenac, 5- Hydroxyibuprofen, 6- Ibuprofen, 7- Naproxen, 8- Nimesulide, 9- Ketoprofen, 10- Salicylic acid,11- Ciproﬂoxacin, 12- Enroﬂoxacin, 13- Trimethoprim, 14- Sul-
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3-  Norsertraline, 24- Norﬂuoxetine, 25- Carbamazepine, 26- Fluoxetine, 27- Sertra
0,11-Epoxycarbamazepine).
ively. Therefore, mixtures of organic solvents with ultrapure water
t different proportions (1:1 and 3:7 (v/v)) were tested. The mix-
ure of ultrapure water and acetonitrile improved the recoveries of
ll ﬂuoroquinolones (>80%) and recoveries remained constants for
oth tested proportions (1:1 and 3:7 (v/v)). When ultrapure water
as mixed with methanol in the proportion (1:1, v/v) recoveries
ere only higher for ciproﬂoxacin, while for the proportion 3:7
v/v), recoveries increased for all ﬂuoroquinolones with 49.1, 58.2,diazine, 19- Sulfamethoxazole, 20- Oﬂoxacin, 21- Clarithromycin, 22- Azithromycin,
8- Citalopram, 29- Venlafaxine, 30- Paroxetine, 31- Trazodone, 32- Diazepam, 33-
and 65.4% for ciproﬂoxacin, enroﬂoxacin, and oﬂoxacin, respec-
tively.
Since the chromatographic separation of antibiotics and psychi-
atric drugs embracing the use of 0.1% of formic acid in the aqueous
eluent, it is important to check the recoveries with the acidiﬁ-
cation of the aqueous phase in the reconstitution solvent. Thus,
mixtures of 0.1% of formic acid in ultrapure water with acetoni-
trile or methanol were also tested, using the proportion 3:7 (v/v),
due to the high recoveries obtained with this proportion. No signiﬁ-
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ant improvements were noticed with the acidiﬁcation of ultrapure
ater and recoveries between 85 and 102% and from 52 to 61%
ere obtained using acetonitrile and methanol as organic solvent,
espectively. Therefore, the mixture of acetonitrile and ultrapure
ater in the proportion of 3:7 (v/v) was selected as reconstitution
olvent.
.2.3. Sample volume breakthrough
The study of the breakthrough volume was performed using
urface water (river water) and wastewaters (WWTP  inﬂuent and
fﬂuent). Volumes between 25 and 500 mL  (river water) and from
5 to 250 mL  (wastewaters) were tested. Results of recoveries are
hown in Fig. 3.
The  mean recoveries obtained were: 82.9 (25 mL), 78.7 (50 mL),
1.3 (100 mL), 79.0 (250 mL), and 68.2% (500 mL)  for river water;
1.0 (25 mL), 81.0 (50 mL), 76.6 (100 mL), and 69.0% (250 mL)  for
WTP  efﬂuent; and 76.8 (25 mL), 75.1 (50 mL), 53.7 (100 mL), and
4.0% (250 mL)  for WWTP  inﬂuent, with RSD values lower than 10%.
The recovery of acetaminophen decreased with the increase of
he sample volume, which is in agreement with previous works
20,32]. Acetaminophen showed the same behaviour in all types of
ater tested. Even with a recovery lower than 50%, acetaminophen
s detected in environment due to its high consumption. Therefore
50, 100, and 50 mL  were the sample volumes selected for sur-
aces waters, WWTP  efﬂuent and WWTP  inﬂuent, and recoveries
etween 30.3% (acetaminophen) and 101% (ibuprofen, naproxen,
nd nimesulide) for river water, 28.4 (acetaminophen) to 116%
acetylsalicylic acid) for WWTP  efﬂuent, and 32.6 (acetaminophen)
o 122% (acetylsalicylic acid) for WWTP  inﬂuent were achieved.
.3. Method performance
Linearity, MDLs, MQLs, repeatability, reproducibility, recoveries
nd ME  were performed. The linearity of the method was  estab-
ished by setting calibration curves (solvent and matrix matched)
sing linear regression analysis with concentrations in the range of
–250 g L−1. All pharmaceuticals gave good ﬁts (R > 0.994). Cal-
bration standards were measured at the beginning and at the
nd of each sequence. To check the signal stability, one calibra-
ion standard (100 g L−1) was injected repeatedly throughout the
equence. Solvent blanks consisting of acetonitrile were preparedn the different aqueous environmental matrices.
to run after every ﬁve samples for monitoring the instrumental
background.
Recoveries were evaluated at three levels of fortiﬁcation for
each type of water sample. The obtained results are summarized
in tables SM3a and SM3b (Supplementary material). RSD values
lower than 10% were achieved for all water samples. Generally,
good recoveries were obtained for all the studied pharmaceuti-
cals (>50%), except for acetaminophen in all type of water samples
and for sulfapyridine, sulfamethazine, sulfamethoxypiridazine and
sulfadimethoxine in seawater. Recoveries ranged from 50.5 (sul-
famethoxazole) to 100% (ketoprofen, nimesulide, and paroxetine)
for bottled water, 50.1 (sulfamethoxazole) to 98.0% (ciproﬂoxacin)
for tap water, 56.6 (sulfadiazine) to 109% (naproxen) in seawa-
ter, 47.8 (sulfamethoxazole) to 102% (ciproﬂoxacin) for river water,
50.8 (10,11-epoxycarbamazepine) to 129% (acetylsalicylic acid) in
WWTP  efﬂuent, and 51.6 (10,11-epoxycarbamazepine) to 122%
(acetylsalicylic acid) in WWTP  inﬂuent, respectively. The developed
method showed good reproducibility, with RSD values ranging
from 0.05 to 10% in all matrices (Table SM3, Supplementary mate-
rial). Similar recoveries were achieved by M.  Gros et al. [33] for
surface water, WWTP  efﬂuent, and inﬂuent, ranging from 60 to
142%, from 62 to 121%, and from 50 to 151%, respectively, and
by Cai et al. [11] for drinking water, showing recoveries between
61.4-124.3% for most of the selected pharmaceuticals. The obtained
recoveries for seawaters are also in agreement with literature,
where recoveries from 26.6 to 229% were reported [34].
MDLs  and MQLs varied depending on the aquatic environmen-
tal matrix considered and higher values were achieved for WWTP
efﬂuent and inﬂuent (Table SM4, Supplementary material). In gen-
eral, MDLs ranged from 0.02 ng L−1 for  salicylic acid, naproxen,
and nimesulide, in bottled water, to 185 ng L−1 for  norsertraline
in WWTP  inﬂuent, and MQLs varied between 0.04 ng L−1 for  sal-
icylic acid, in bottled water, and 562 ng L−1 for norsertraline, in
WWTP inﬂuent. It should be highlighted that the highest MDLs and
MQLs were obtained to the metabolites carboxyibuprofen, hydrox-
yibuprofen, and norsertraline and the pharmaceuticals ibuprofen
and ciproﬂoxacin (up to 185 and 562 ng L−1, respectively).
Three different concentrations (25, 50, and 100 g L−1) were
used and twelve successive injections in one day and triplicate
injections in six consecutive days were performed for the intra-
and inter-day precision. The overall method precision was satis-
factory, with RSD values ranging from 0.6 (hydroxyibuprofen) to
 Table 1a
Concentration  of pharmaceuticals, in ng L−1 , detected in bottled water, tap water, and seawater.
Pharmaceuticals Concentration (ng L−1 ) ± RSD(%)
Bottled water Tap water Seawatera
BW1  BW2  TW1  TW2  SW1-B SW2-B SW3-G SW4-G SW5-Y SW6-Y
NSAIDs/analgesics
Salicylic acid 30.6 ± 5.12 21.2 ± 4.23 66.0 ± 5.10 39.4 ± 1.91 169.1 ± 4.28 91.3 ± 2.37 73.7 ± 5.90 92.6 ± 5.15 73.4 ± 4.18 137.5 ± 0.89
Acetylsalicylic acid n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5.12 ± 7.13 n.d. n.d.
Acetaminophen n.d. n.d. n.d. n.d. 224.6 ± 0.37 98.6 ± 3.81 53.2 ± 6.37 156.3 ± 6.04 269.7 ± 0.61 59.4 ± 3.06
Hydroxyibuprofen n.d. n.d. n.d. n.d. 29.0 ± 2.87 30.8 ± 7.71 27.3 ± 1.79 30.3 ± 8.12 98.9 ± 5.62 27.6 ± 8.57
Carboxyibuprofen n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 270.4 ± 3.97 n.d.
Ketoprofen n.d. < MDL  < MDL  < MDL  11.3 ± 6.41 17.7 ± 6.98 11.2 ± 0.52 11.9 ± 5.94 12.9 ± 4.97 12.3 ± 5.61
Naproxen  n.d. n.d. n.d. n.d. 17.5 ± 1.05 n.d. n.d. 23.9 ± 2.87 177.7 ± 6.59 17.4 ± 0.16
Nimesulide n.d. n.d. n.d. n.d. 5.2 ± 9.12 n.d. n.d. n.d. n.d. n.d.
Diclofenac n.d. n.d. n.d. n.d. n.d. n.d. 2.36 ± 2.87 n.d. 3.99 ± 4.76 n.d.
Ibuprofen <MDL <MDL <MDL <MDL 27.6 ± 0.47 23.8 ± 0.63 32.7 ± 3.39 33.6 ± 7.73 40.6 ± 4.10 9.4 ± 4.3
Psychiatric drugs
Venlafaxine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Trazodone n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Citalopram n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Paroxetine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Norﬂuoxetine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Norsertraline n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Fluoxetine 0.27 ± 5.66 n.d. n.d. 1.90 ± 1.24 n.d. 0.27 ± 5.96 0.25 ± 6.24 0.74 ± 5.16 0.27 ± 1.81 n.d.
Sertraline n.d. n.d. n.d. n.d. n.d. < MDL  n.d. n.d. n.d. 8.09 ± 9.18
10,11-Epoxycarbamazepine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Carbamazepine 22.1 ± 2.32 n.d. 22.3 ± 1.52 20.0 ± 0.580 n.d. n.d. n.d. n.d. n.d. 28.3 ± 3.12
Diazepam  n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Antibiotics
Trimethoprim n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Oﬂoxacin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Ciproﬂoxacin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Enroﬂoxacin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Sulfadiazine n.d. n.d. n.d. n.d. <MDL <MDL <MDL <MDL <MDL <MDL
Sulfapyridine n.d. n.d. n.d. n.d. <MDL <MDL <MDL <MDL <MDL n.d.
Sulfamethazine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Sulfamethoxypiridazine n.d. n.d. n.d. n.d. n.d. n.d. <MDL <MDL <MDL <MDL
Azithromycin n.d. n.d. n.d. n.d. <MDL <MDL n.d. <MDL <MDL <MDL
Clarithromycin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Sulfamethoxazole n.d. n.d. n.d. n.d. n.d. n.d. 1.65 ± 17.4 <MDL n.d. n.d.
Sulfadimethoxine n.d. n.d. n.d. n.d. n.d. <MDL <MDL <MDL <MDL n.d.
aBeaches classiﬁed as: B-“excellent” with a blue ﬂag, G-“good” with a green ﬂag, and Y-“sufﬁcient” with yellow ﬂag.
Table 1b
Concentration of pharmaceuticals, in ng L−1 ,  detected in river water, WWTP  inﬂuent and efﬂuent.
Pharmaceuticals Concentration (ng L−1)  ± RSD(%)
River WWTP  Inﬂuent WWTP  Efﬂuent
RW1  RW2  IW1  IW2  EW1  EW2
NSAIDs/analgesics
Salicylic acid 89.2 ± 9.13 128.2 ± 8.93 6332.3 ± 3.37 33535.5 ± 5.15 186.7 ± 4.25 126.9 ± 7.90
Acetylsalicylic  acid n.d. n.d. n.d. n.d. n.d. n.d.
Acetaminophen  <MDL 4.9 ± 12.57 30030.4 ± 1.36 615134.9 ± 6.94 736.0 ± 6.80 2139.0 ± 7.79
Hydroxyibuprofen  <MDL n.d. 190.2 ± 0.44 198.4 ± 1.27 284.7 ± 0.97 358.7 ± 1.23
Carboxyibuprofen  n.d. n.d. 41554.0 ± 5.03 120365.0 ± 4.68 n.d. n.d.
Ketoprofen  <MDL <MDL <MDL <MDL 22.3 ± 0.21 55.9 ± 0.35
Naproxen  n.d. <MDL 2078.7 ± 5.17 533.3 ± 2.89 <MDL 110.7 ± 8.82
Nimesulide  n.d. n.d. n.d. n.d. n.d. n.d.
Diclofenac  n.d. n.d. n.d. n.d. n.d. n.d.
Ibuprofen  <MDL <MDL 4389.3 ± 7.44 14124.8 ± 8.52 517.4 ± 8.23 323.7 ± 9.68
Psychiatric drugs
Venlafaxine n.d. n.d. <MDL 15.4 ± 4.19 91.9 ± 6.45 170.9 ± 0.19
Trazodone  n.d. n.d. <MDL 17.7 ± 8.96 7.5 ± 7.94 21.7 ± 11.7
Citalopram  n.d. n.d. n.d. 15.1 ± 1.37 26.1 ± 7.06 61.4 ± 7.98
Paroxetine  n.d. n.d. n.d. n.d. n.d. n.d.
Norﬂuoxetine  n.d. n.d. n.d. n.d. n.d. n.d.
Norsertraline  n.d. n.d. n.d. n.d. n.d. n.d.
Fluoxetine  3.3 ± 0.85 3.7 ± 3.92 5.2 ± 1.52 8.8 ± 1.15 12.9 ± 6.78 27.5 ± 4.93
Sertraline  <MDL <MDL n.d. n.d. <MDL n.d.
10,11-Epoxycarbamazepine n.d. n.d. n.d. n.d. n.d. 88.0 ± 3.36
Carbamazepine  32.9 ± 3.27 34.4 ± 0.16 66.2 ± 4.54 110.9 ± 6.12 98.5 ± 6.88 244.9 ± 3.34
Diazepam  n.d. n.d. n.d. n.d. n.d. n.d.
Antibiotics
Trimethoprim n.d. n.d. n.d. n.d. n.d. 59.3 ± 13.0
Oﬂoxacin  n.d. n.d. n.d. n.d. n.d. n.d.
Ciproﬂoxacin  n.d. n.d. 118.9 ± 0.30 n.d. 96.6 ± 9.29 n.d.
Enroﬂoxacin  n.d. n.d. n.d. n.d. n.d. n.d.
Sulfadiazine  n.d. n.d. n.d. <MDL n.d. n.d.
Sulfapyridine  n.d. n.d. n.d. n.d. n.d. n.d.
Sulfamethazine  n.d. n.d. n.d. n.d. n.d. n.d.
Sulfamethoxypiridazine  n.d. n.d. n.d. n.d. n.d. n.d.
Azithromycin  n.d. n.d. n.d. 67.0 ± 4.59 n.d. 11.4 ± 12.3
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.73% (norsertraline) for intra-day and 4.29 (salicylic acid) to 11.1%
norsertraline) for inter-day precision (Table SM5, Supplementary
aterial).
Matrix effects (ME) is one signiﬁcant drawback in ESI MS quanti-
ative analysis, because the ESI source is highly susceptible to other
omponents present in the matrix. The ME  could be deﬁned as the
hange in UHPLC–MS/MS response of an analyte, by suppression
r enhancement of the signal, caused by coeluting matrix com-
ounds, relative to an injection of a pure standard [35]. ME  were
valuated for the different aquatic environmental matrices and
esults are shown in Fig. 4 and Fig. SM3  (Supplementary material).
t was observed ME  in all the studied matrices, which, in general,
as expressed as an ion suppression for almost all the pharma-
euticals. Although compounds like ciproﬂoxacin, sulfamethazine,
ulfamethoxine, oﬂoxacin, norsertraline, norﬂuoxetine, venlafax-
ne, diazepam, ibuprofen and nimesulide showed ion enhancement
or different matrices, mainly wastewaters (WWTP  inﬂuent and
fﬂuent). In the case of ibuprofen and nimesulide, the ion enhance-
ent was more pronounced in seawater (Fig. 4). This could be
ustiﬁed by the high salt content of this matrix, suggesting that
he salt residues might still be present in the sample extract, co-
luting with the selected analytes [36–39]. On the other hand,
on suppression was usually more evident for matrices such as
WTP  efﬂuent and river water, being this effect more pronouncedor NSAIDs/analgesics (Fig. 4). Nevertheless, antibiotics like clar-
thromycin, azithromycin and most of the sulfonamides as well as
he antidepressants venlafaxine and citalopram and the metaboliten.d. n.d. 70.4 ± 5.75
224.1 ± 4.30 n.d. 73.4 ± 9.42
n.d. n.d. n.d.
norsertraline also had a marked ion suppression in WWTP  efﬂuent
(Fig. 4).
Evaluating the general ME  observed for the different aquatic
environmental matrices, it was  noticed that ME  were less pro-
nounced (<20%) in bottled water and tap water for the majority of
the selected pharmaceuticals (67% and 58% of pharmaceuticals ﬁt
in this level, respectively), while for surface waters, WWTP  inﬂu-
ent and efﬂuent, more than 50% of the pharmaceuticals had ME
higher than 20%. In fact, due to the high complexity of wastewa-
ters, approximately one-third of the compounds showed ME higher
than 50% (Fig. SM3, Supplementary material).
3.4. Application to real samples
A total of sixteen samples embracing different types of water
were analyzed using the developed analytical methodology. In
Tables 1a and 1b, the concentration of the pharmaceuticals detected
in each analyzed samples is in bold. It was  possible to detect
pharmaceuticals in all the considered aquatic environmental matri-
ces, including drinking water. In fact, pharmaceuticals such as
carbamazepine, ﬂuoxetine, ibuprofen and ketoprofen, and the
metabolite salicylic acid were found in bottled and tap waters, at
concentrations up to 30.6 and 66.0 ng L−1, respectively (Table 1a).
Concentrations were higher in tap water with salicylic acid, carba-
mazepine, and ﬂuoxetine reaching concentrations of 66.0, 22.3, and
1.97 ng L−1, respectively. Similar concentrations of carbamazepine
were detected in drinking water of China [11], while for salicylic
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[cid, carbamazepine and ﬂuoxetine the levels found in France [40],
taly [41], and USA [42] were lower than those reported herein.
harmaceuticals have already been detected in bottled water in
pain, though, contrarily to what happen in this study, always at
oncentrations below MQL  [43].
Six seawater samples were collected in beaches with differ-
nt bathing water quality (excellent, good and sufﬁcient) [19]
nd it was possible to detect all the NSAIDs/analgesics, as well
s six antibiotics, and three psychiatric drugs in at least one
ample (Table 1a). In fact, the NSAIDs/analgesics acetaminophen,
buprofen and ketoprofen and the metabolites salicylic acid
nd hydroxyibuprofen were detected in all the analyzed sam-
les. NSAIDs/analgesics were found at concentrations ranging
rom 2.36 ng L−1 (diclofenac) to 270.4 ng L−1 (carboxyibuprofen),
hereas  the levels of psychiatric drugs varied between 0.25 ng L−1
nd 28.3 ng L−1, for ﬂuoxetine and carbamazepine, respectively.
ulfonamides were the most detected antibiotics in seawater, but
nly sulfamethoxazole was quantiﬁed (1.65 ng L−1). Similar ﬁnd-
ngs were reported for antibiotics in the Mediterranean coast [44],
hile the NSAID ibuprofen was found at higher levels [45], and
cetaminophen and salicylic acid at lower concentrations [9,46]
han those reported herein. On the other hand, carbamazepine was
etected at similar concentrations (4.0–26.3 ng L−1) in seawater
rom Canada [47], while higher concentrations of ﬂuoxetine were
eported in Paciﬁc Ocean [48].
The results obtained for river water and wastewaters (WWTP
nﬂuent and efﬂuent) are shown in Table 1b. In river water, the high-
st concentrations were reported for the metabolite salicylic acid
89.2–128.2 ng L−1), followed by the antiepileptic carbamazepine
32.9–34.4 ng L−1) and the analgesic acetaminophen (<MDL-
.90 ng L−1). Clarithromycin was the only antibiotic detected in
iver water, but below MDL  (Table 1b). Similar ﬁndings were
eported for Spanish rivers [22] and in Jamaica Bay [49].
Regarding  wastewaters, in WWTP  inﬂuents, the highest con-
entrations were found for the NSAIDs/analgesics acetaminophen,
aproxen, and ibuprofen, and for the metabolites carboxy-
buprofen and salicylic acid, reaching levels up to 615 g L−1
acetaminophen) (Table 1b); while in WWTP  efﬂuents, phar-
aceuticals like acetaminophen, ibuprofen and carbamazepine
nd the metabolites salicylic acid and hydroxyibuprofen showed
he highest concentrations (up to 2139 ng L−1). Similar levels of
SAIDs/analgesics were reported in WWTP  efﬂuents in Spain [35],
hile in Canada higher levels were found [50]. Identical concentra-
ions of carbamazepine and ﬂuoxetine were also found in Spanish
35] and Chinese wastewaters  [51], respectively.
. Conclusions
Pharmaceuticals are one of the major groups of emerging con-
aminants that are commonly found and targeted in environmental
nalysis. A proper sample preparation combined with LC–MS/MS
nalysis can ensure the sensitivity and accuracy required for the
race analysis of pharmaceuticals in the environment.
Gathering a SPE extraction protocol using a polymeric sorbent
Strata-X) with the UHPLC–MS/MS technology for chromatographic
nalysis allowed getting a fast, reliable, sensitive, robust and accu-
ate multi-residue analytical method for the simultaneous analyses
f trace levels of human and veterinary pharmaceuticals in a wide
ange of aquatic environmental matrices. The developed analyt-
cal method enabled the simultaneous analysis of a total of 33
harmaceuticals and metabolites belonging to three therapeutic
roups and having important differences in their chemical struc-
ures. Recoveries higher than 50% were obtained for the selected
harmaceuticals and metabolites for all the aqueous environmental
atrices, with the exception of acetaminophen; and sulfapyridine,
[sulfamethazine, sulfamethoxypiridazine, and sulfadimethoxine in
seawater. MDLs in the low ng L−1 range  were achieved, allowing the
application of the developed tool in the monitoring of trace levels
of pharmaceuticals.
The optimized method was applied to six types of water embrac-
ing drinking water, surface water and wastewater, in a total of
sixteen samples, proving to be an interesting tool to gather data
on the different ways of entrance of pharmaceuticals into the
environment as well as to evaluate the impact and distribution
of either human and veterinary medicines in the aquatic envi-
ronment, allowing to track the presence of pharmaceuticals and
their metabolites among the water cycle. The obtained results
showed a widespread occurrence of pharmaceuticals in the aquatic
environment, being NSAIDs/analgesics the therapeutic group most
frequently detected in all aqueous environmental matrices, fol-
lowed by psychiatric drugs and antibiotics.
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